Your institution may have access to this item. Find your institution then sign in to continue.
Title
Immunotherapy Extends Survival in Uveal Melanoma.
Abstract
The article focuses on patients with uveal melanoma who were treated with tebentafusp, an investigational immunotherapy, lived a median longer than those in comparison groups, researchers has reported in study fundings presented at the American Association for Cancer Research 2021 annual meeting.